Author
Listed:
- Amit Kaura
- Adam Hartley
- Vasileios Panoulas
- Ben Glampson
- Anoop S V Shah
- Jim Davies
- Abdulrahim Mulla
- Kerrie Woods
- Joe Omigie
- Anoop D Shah
- Mark R Thursz
- Paul Elliott
- Harry Hemmingway
- Bryan Williams
- Folkert W Asselbergs
- Michael O’Sullivan
- Graham M Lord
- Adam Trickey
- Jonathan AC Sterne
- Dorian O Haskard
- Narbeh Melikian
- Darrel P Francis
- Wolfgang Koenig
- Ajay M Shah
- Rajesh Kharbanda
- Divaka Perera
- Riyaz S Patel
- Keith M Channon
- Jamil Mayet
- Ramzi Khamis
Abstract
Background: There is limited evidence on the use of high-sensitivity C-reactive protein (hsCRP) as a biomarker for selecting patients for advanced cardiovascular (CV) therapies in the modern era. The prognostic value of mildly elevated hsCRP beyond troponin in a large real-world cohort of unselected patients presenting with suspected acute coronary syndrome (ACS) is unknown. We evaluated whether a mildly elevated hsCRP (up to 15 mg/L) was associated with mortality risk, beyond troponin level, in patients with suspected ACS. Methods and findings: We conducted a retrospective cohort study based on the National Institute for Health Research Health Informatics Collaborative data of 257,948 patients with suspected ACS who had a troponin measured at 5 cardiac centres in the United Kingdom between 2010 and 2017. Patients were divided into 4 hsCRP groups (
Suggested Citation
Amit Kaura & Adam Hartley & Vasileios Panoulas & Ben Glampson & Anoop S V Shah & Jim Davies & Abdulrahim Mulla & Kerrie Woods & Joe Omigie & Anoop D Shah & Mark R Thursz & Paul Elliott & Harry Hemming, 2022.
"Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study,"
PLOS Medicine, Public Library of Science, vol. 19(2), pages 1-17, February.
Handle:
RePEc:plo:pmed00:1003911
DOI: 10.1371/journal.pmed.1003911
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pmed00:1003911. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosmedicine (email available below). General contact details of provider: https://journals.plos.org/plosmedicine/ .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.